NeuroPace
NPCE
NeuroPace (NPCE) news
Recent news
NeuroPace drops 16% postmarket on negative FDA guidance
AInvest Wire · Jul 28, 2026NeuroPace - to submit submission issue request and amend PMA supplement
AInvest Wire · Jul 28, 2026NeuroPace Inc: Mizuho initiates coverage with outperform rating; target price $22
Mizuho Securities has initiated coverage of NeuroPace Inc (NASDAQ: NPCE) with an "outperform" rating and a target price of $22 per share, according to a recent report[1]. The firm cited the company’s progress in advancing its neurotechnology platform and expanding its therapeutic applications as…
AInvest Wire · Jul 23, 2026NeuroPace raises 2026 revenue guidance
AInvest Wire · May 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.